The Technology to Power Natural Healing

Nitric Oxide is Coming of Age

Origin - with a patented platform technology that enables the simple delivery of NO in the clinic - is uniquely positioned to dominate several key clinical verticals in this exciting growth market.


Company & History

Origin is a privately-held, clinical-stage biotechnology company founded in June 2010 to develop and commercialize a novel, patented medical technology - delivering therapeutic molecules generated right at the point of care. Our technology is based on Nobel prize-winning research and is designed to surpass current standards of care in efficacy, side effects, and/or cost-effectiveness across a wide range of indications.

Plasma medicine is an innovative and emerging field combining plasma physics, life sciences and clinical medicine to use plasma for therapeutic applications. It is the subject of advanced study at major academic institutions in the United States, Russia, Germany, Japan, the United Kingdom, France and Italy.

Our investigations led us to a technology that delivered therapeutic doses of nitric oxide with clinical success in wound-healing in Russia and Eastern Europe, winning the Russian Federation Prize for Science.

We secured an option to acquire the US patent for the technology in 2011, and in 2014 raised funds from institutions in the United Kingdom that enabled us to exercise this option, acquire and improve the technology for ourselves and embark on our regulatory strategy. We selected skin and soft-tissue infections and wound healing as our initial target areas, with a first indication in diabetic foot ulcers.

We then agreed on a regulatory pathway with the FDA, enhanced the technology and commenced formal clinical trials that, if successful, will lead to the submission of a premarket approval application.

Along the way, we have strengthened our Board of Directors and management team, and widened the scope of our commercial activities.


A First Class Team


Origin is managed by a team with decades of experience in life sciences and in building value for shareholders. They have had demonstrable success:

  • Developing and marketing pharmaceuticals and medical devices, including wound-care products

  • Administering hospitals and major healthcare delivery systems

  • Growing and operating both private and publicly traded businesses


For investment inquiries, please contact our CFO, Johnny Fernandes, at or +1 609 250 6005